Newsroom | 12118 results
Sorted by: Latest
-
CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA), — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced the award of inducement grants. On February 24, 2026, as an inducement material to acceptance of employment with CareDx, 35 new employees were awarded restricted stock units (RSUs) for an agg...
-
PADCEV™ + Keytruda® Cuts Risk of Recurrence or Death by Nearly 50% in Cisplatin-Eligible Muscle-Invasive Bladder Cancer
NEW YORK & TOKYO--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced positive results from the Phase 3 EV-304 clinical trial (also known as KEYNOTE-B15) for PADCEVTM (enfortumab vedotin), a Nectin-4 directed antibody-drug conjugate, in combination with Keytruda® (pembrolizumab), a PD-1 inhibitor, in patients with muscle-invasive bladder cancer (MIBC) eligible for cisplatin-based chemotherapy. Perioperative...
-
Four Feinstein Institutes Scientists Honored as National Academy of Inventors Senior Members
MANHASSET, N.Y.--(BUSINESS WIRE)--In recognition of their impact on society through the successful production, patenting and commercialization of groundbreaking technologies, four esteemed scientists from Northwell Health’s Feinstein Institutes for Medical Research – Lior Brimberg, PhD; Jared M. Huston, MD; Stavros Zanos, MD, PhD; and Theodoros Zanos, PhD – have been named to the prestigious 2026 class of Senior Members by the National Academy of Inventors (NAI). This significant recognition hi...
-
Quanta System Inc.: Strengthening the U.S. Presence of Italian Laser Technology
SAMARATE, Italy--(BUSINESS WIRE)--Quanta System Sp.A., a leading company in laser technologies for surgery, dermatology, and aesthetic medicine, 100% Made in Italy and part of the El.En. Group, announced today the establishment of Quanta System Inc., a new US entity based in North Carolina, officially operational as of March 1, 2026. The creation of a direct presence in the US Surgical and Urology market, represents a strategic step in the international expansion of the organization. By launchi...
-
OSSTEC Appoints Dr. Nick Pachuda to Board and Establishes US Operations Ahead of US Market Entry
LONDON--(BUSINESS WIRE)--OSSTEC Appoints Dr. Nick Pachuda to Board and Establishes US Operations Ahead of US Market Entry...
-
Wyss Geneva Spin-Off Clee Medical sichert sich Startkapital für Echtzeit-Bildgebung in der Gehirnchirurgie
GENF--(BUSINESS WIRE)--Das Wyss Center for Bio and Neuroengineering Geneva gab heute den erfolgreichen Abschluss der Startkapital-Finanzierungsrunde für Clee Medical SA bekannt, ein Schweizer Spin-off-Unternehmen im Bereich Neurotechnologie, das ultrahochauflösende Echtzeit-Bildgebung für die Gehirnchirurgie entwickelt. Die Runde wurde vom High-Tech Gründerfonds (HTGF) angeführt, unter Beteiligung der Zürcher Kantonalbank (ZKB), Kickfund, FONGIT und Venture Kick, die sich den bestehenden Invest...
-
Resumen: Clee Medical, una empresa derivada de Wyss Geneva, obtiene financiación semilla para llevar la visión en tiempo real a la cirugía de cerebro
GINEBRA, Suiza--(BUSINESS WIRE)--Wyss Center for Bio and Neuroengineering Geneva anunció hoy el cierre exitoso de la ronda de financiación semilla de Clee Medical SA, una empresa derivada de neurotecnología suiza que desarrolla imágenes intraoperatorias en tiempo real de alta resolución para cirugías cerebrales. La ronda fue liderada por High-Tech Gründerfonds (HTGF) y contó con la participación de Zürcher Kantonalbank (ZKB), Kickfund, FONGIT y Venture Kick, que se unieron a los inversores exis...
-
Riassunto: Wyss Geneva, con il suo spin-off Clee Medical, si aggiudica un finanziamento iniziale mirato ad arricchire la neurochirurgia con la visione in tempo reale
GINEVRA--(BUSINESS WIRE)--Il Wyss Center for Bio and Neuroengineering Geneva oggi ha annunciato la riuscita chiusura del round di finanziamento iniziale (seed) di Clee Medical SA, spin-off neurotecnologico svizzero impegnato nello sviluppo di soluzioni ad altissima risoluzione per l'imaging intraoperatorio in tempo reale destinate al settore della chirurgia cerebrale. Il round era guidato da High-Tech Gründerfonds (HTGF) con la partecipazione di Zürcher Kantonalbank (ZKB), Kickfund, FONGIT e di...
-
Samenvatting: Het van Wyss Geneva afgesplitste Clee Medical verkrijgt startkapitaal om realtime beeldvorming bij hersenchirurgie mogelijk te maken
GENÈVE--(BUSINESS WIRE)--Het Wyss Center for Bio and Neuroengineering Geneva heeft vandaag bekendgemaakt dat de seed-financieringsronde van Clee Medical SA, een Zwitserse spin-off op het gebied van neurotechnologie die realtime intraoperatieve beeldvorming met ultrahoge resolutie voor hersenchirurgie ontwikkelt, succesvol is afgerond. De ronde werd geleid door High-Tech Gründerfonds (HTGF), met deelname van Zürcher Kantonalbank (ZKB), Kickfund, FONGIT en Venture Kick, die zich aansloten bij bes...
-
Clee Medical, une filiale du Wyss Center à Genève, obtient un financement d'amorçage pour apporter une vision en temps réel à la chirurgie cérébrale
GENÈVE,--(BUSINESS WIRE)--Le « Wyss Center for Bio and Neuroengineering Geneva » a annoncé aujourd'hui la clôture réussie du tour de table d'amorçage de Clee Medical SA, une spin-off suisse de neurotechnologies développant une imagerie peropératoire en temps réel à ultra-haute résolution pour la chirurgie cérébrale. Ce tour de table a été mené par High-Tech Gründerfonds (HTGF), avec la participation de la Banque cantonale de Zurich (ZKB), de Kickfund, de FONGIT et de Venture Kick, qui rejoignen...